Prevalence of hepatitis B and hepatitis C, and their ...

4 downloads 0 Views 219KB Size Report
3- Altamimi W, Altraif I, Elsheikh M, Alkshan A, Qasem. L, Sohaibani M. Prevalence of HBsAg and Anti-HCV in Saudia blood donors. Annals of Saudia Medicine.
(

)

C B + 1 2 3 456#7 ! $ + $ /

0!# +

!-./

!3 : ;

* ! $ +,%&# ' ( ) * ! $ +

!" !# ! $

* + 7 87 9 45 7 ! $

!

I 7 I !I 7 4I 7 !IS; JI 7

C ; .) C D E F! G $ 7 ; 1 > ?!# ; @ AB C 7 > 5 I$ O37 JC !5P Q&.R7N.( 1 >1 5C C & C7 J K +7)>7 JC LMCD 50 7 7!# C B O5B T> U 5 3 !C V C .R S 4 7 .) > J5; 1 5 C !S; J 7 .O37 ) G E 7 &5K 37 ; K) $7)>7 5 ? ) ; "

I; = IY 7 AI$! IC ) $ ./7! ; ) $7)>7 ,, X ) !W . C -5( B U 7 ) G E 7 .R S O5B T> C K R? 7A5 3 !C 3 5R 7 1 >L ? [ 37 !C .) 3 !C B Z 1 >= 3 9 &5K C B O5B T> O"\ 7 .) G E 7 > 1 !C 7A 27 : C (Anti-HCVAb)C O5B T> (HBsAg)B ) ; !S; J 7 .) #!K 7! )E L ? O*B " 537A5R7!B 1)5 B 1 >: C N5B!B C !I> I 7 7!# ) !K Q7!M 37 7!#7 ) !W 7 ; @ AB 7 8! ] 3 YC 3 + 07!/ YC 3 ) .) "3 * SPSS 7A#7 G! (Chi-square) 1 $ ? _3 B ? 7 ^ #$

G IE 7 7 aIW .)I C O"\ HCVAb !- X O"\ HBsAg !- ``Z 7A 27 : C $ 7 6 > # !I> U 5 .) ? O3 C )( X/ , + HCVAb U 5 )( X/ + HBsAg U 5 1)5 B 1 >L ? !I> !IS; J 7 4 !Bc . C 7 ! 65C 7 ! O5B T> U HCVAb OI"\ HBsAg !IK . C dK = 3 9 e AT 7) $ G E 7 YC 3 07!/ J YC 3 N5B!B C +O"\ '

OIg/

/ / / / +',

-

% &

>L> W $ g 65W +) C !S; J ) f / e 7 ) $7)>7 ^ 7 > f . ! dW G E 7 >O - 4 7 U 5 C !h J 7 C 7! > g B C i ; J ^ j "B 7 3 !C 7! 7 +C O5B T> + B O5B T> + ; 17)>7 :* ) + ()

!" A B!BC :*

0123 + / 4 " !5

47!, ()*

6

47!, 896: ;' 1?@+

+',

-

./+ ()*

+',

-

: :

!" #$% &' : E D :8. (* 47!, ()* 47!, ()* +', !" A B!BC :* G!.@H PhD 'F?@+ 47!, ()* +', !" A B!BC :* 8 ' = G6: I !" A B!BC :* 47!, 896: ;' 1?@+ 8" ./ (6 + J 26 * 47!, ()* +', !" A B!BC :* 8- 1? KL ;'

L

( (F W = " P * -

>( 6 P.5 2 6 `5 0 +'= 8/ "

B.@+ 4 K / '3' ->(@ J /+ " Y )p . , ; F@+ D - / 8j 47!, 4 ./+

4'5 Q : " 4 @+ - 4'!
4+' 2= P" 4'5 .( )(2" 8 A F@ R ; * K+ 8@'5

! M- 8 @+ + X! !\ o C P" P\ ` X + Vm 6

0 +'= + X +

Y4' 5 Q : >+ K+

4' 5 B.@+ :* P" >(22* P\3+ 4'5 >(22*+(-+ [
'

.(2. , + O Z KL ' )

K+ > a./+ "

Y (% +' s $ Y896:M@+(@ * ; F@+ PB" / Y8V+ 3 / X. Y8"'9 5 Y - !^ 8 23 G 6 X.6+ )p Z

KL + + +

+ >( @

f +: +; @

YP \ `

+ 4? @u /D ) a@ IDfI +: n+

(6 _+ %./+

* 4' KL K+ A =7j+ 8/ " b3 .( , > a./+ SPSS

>(6 + d / 4'5 >(22*+(-+

"

f K+

.@ .( @ '" (% / ) DDI )p HBsAg (( ] f/ ) a@ )p HCVAb Z

f/I ) a@ f Y ) Z

KL + + (( ]

KL ; F@+ K+ e .(@(6

! " `5

- @'a= P< 3 K+

(]

(6 *h (]

[!

f 4' K'a @+

4+ +

(!

-

4' 5 4 ,(22*+(-+ HBsAg

(]

/I ( ] f/D [!

+:,

(HBsAg) B

.( )(6

+:,

g'!6 X + 4+ 9 -

+' g'!6 X!2c d- .(D) '" fff

4' 5 4 ,( 22*+(-+

!"

.( )( ,

/ Y4' 5 4 ,( 22*+(-+ 4 !

/f K+ ! 6

@'a= +P\ `

P " P \ 3 4L

/

! M-

-

! M- P " 7. "+ `5 Y(2-

82!@+' O 8 / " J /+ " P* 8 V

/

(]

(HCV) C

! M- >(6

P" I

4, ,

/

.( ) '" X db

X i 6 Y> ' L 8@'5

i 6 4+' 2= P " C

X

->

-4' 5 8/ " K+ 0)O C

8 +( -+

4K'/

K+ 8 '9 /'@' '*

.(@( 6 P) / C 0 +'= K+ G - 8@+ +

.(2. - 0!5

)p

Y4' 5 Q : PB" / ( 2@ >( 6 P.5 2 6 `5 0 +'=

FV PB" / Y /

_7\ +[\]

a + 4' K'a @+ K+ e

! M- g'! 6

)p

+' P !+

! M- > ' " 4'5

- G@ "

'j P" .( ) /+ >(6 P.5 26 4'5 Q : K+ (\" 8" ^

+

9 L YX +H !k@ - '?* K+ 8l\"

X + P " 7. "+ (] 8@ b3

f

8@'5



! MP*

L Q :

/+ >( 6 m `

!"

+ HCV g'!6

4 ,( 2- [( 6

L "(]

+ 82/ 8@+ +

8@+ + X + .( ) /+ 4 ,(22*+(-+

.(D) /+ > '" (]

/ .' "

P\ `

>( 6 ; F@+ A \ ` K+ . * P* ( L / P" (] 4 ! )p HBsAg ( ] /I 8 @+ + "4 , , 4'5 4 ,(22*+(-+

/I / ±

/I X!1@ ! 'j P"

HBsAg

4' 5 4 ,(22*+(-+ X!"

-> ,

/f :!@ fff

/

K+ !6

/

)p HBsAg + + 82/ X!1@ !

/D

)p HBsAg P" 7.)

(0 * K+ % )

( 2@ 8( 6 ; F@+ A \ ` P" ? ( 6 ; F@+ P \ `

Pc ,+ .(@+> +

>( 6 +: , ( ] f/ K+ . * HCVAb g'!6 Y ff g'! 6 : !@ 4 , , >( 6 ; F@+ P \ ` .( f) /+ X .? !" Y>( 6 P.5 2 6 `5 0 +'= 8 @+ + )p HBsAg +'

d -

P*

/+ 4 ba]+

K) $7)>7

O"\ HBsAg )(

7).B

D /

D

f Y:!@ 4 '(22*+(-+ [(6 ; F@+ 8/ " P" ? P\ `

- +(@ . /+ A 9@

8"'9 5 Y8B : (%

)p HBsAg + + P./ . /+ >(6 > L (3

*h + 8V+ 3 0 = PB" / Y )p HBsAg +' (] D

(@+' 8

)p HCVAb

FV PB" / + + W@'

.( @ ')@ z'9? 8 23 J

k@ K+

[ ! P " P* '" 8V+ 3 0 = PB" / Y )p HCVAb X + u .@ . 6+ '3 +' (] D/ (] D / 4L

+' s $ Y

`5 0 +'= X i 6 .(@ '"

HCVAb

.( ) '" (] f/D 4'5 4 ,(22*+(-+ 4 ! '

+

)p HCVAb P " 7.) +' (] ! M- g'@ - g'!6 .(@ '"

(0 * K+ %I ) 4 @K K+ .? !" 4+ ...

)p HCVAb +

/ ID/ ± f/ f

D

f

8V+ 3 0 = PB" / 8 j 896:M@+(@ * PB" / P.6 , / f 4'5 Q : PB" / P " 4K' / / X. / FV PB" / ( % +' s $ PB" / 8B : z'9? 8 23 J PB" / 8"'9 5 8 '9/ (@L PB" / 8 '9/'@' '* PB" / 8V+ 3 PB" / 4+(@K PB" /

/ NB | V )p HCVAb +'

)p HCVAb +' K+ (] * ; F@+ PB" / + +

)p HBsAg

g'!6 " Qj 2 :3 4+ + '?* YG H' '! (! + k@ K+ K+ 89 J /+ " . '68 {' C B 8

P * 4+ +

89 H' '! (! +

! M- + " N/'. / A \ ` X .b"

4+ 9 - 8= 2O '$2 K )

.*

.(6

47!, 4 ,(22*+(-+

+:, (]

I Y8@+ + X + Y:!@

+'

4' 5 4 ,( 22*+(-+ C

J

V

B

! M- g'!6 P" P3' " 8v P"

7/ A )~+ K+ 0)O Y4'5 " N) = Y

X + K+ . '6 X! l Z!

P! ]' P? ! - ( 2@

!,4' 5 02 / N /' 8 2 +

4 9 + >( 22*+(-+ G

> +' - 4'c X!2c d- .

b2? ! 4 ,(2

'@ Y( 6 "8

0 = G } ) + 8/ "

b3 8 - Z- v P* (2 @ 8

X + g'! 6 " 1 0 +'= " >+ - P@ 8 b2 P" • 5 .

; F@+ - @'a=

P*

P*

6 4'5

. '68 8@+ (O

9?

.( ) /+

/+ 8 V

.b" P! +

X + Y(@ * > 6+ (\. 8 23

* 6

P " )p HCVAb + + K+ (] D NB Y | V P\ ` G y! - (2.6+ > 6+ - !^ 8 23 G 6 X.6+ *h +

+P `"+ X! 2c PB" / Y

4 ba ]+

>( 6 ; F@+ P\ `

)p HBsAg +

+ K+

Pc ,+ .( D)(@ * 8 @

8 23 G 6 X. 6+ Y )p HBsAg + + K+ (] ID 4 '
)p HBsAg

+: ,

)p HBsAg + + K+ (]

X. 6+ P " 0 K "

HBsAg

+

4+:! X +

.(6 "8 47!, 4 ./+

. *

(@' @

! M-

PB" / Y )p HCVAb +' ( ] I / : !@ 4+ b 1 " ^ >( 2- 4 ? @ + X + .( f)(2.6+ 4' K'a @+

,8

`5 0 = ( 2c ' 3

>( 6

B

>( 6 ; F@+ 8 / "

1" ^

" 4' 5 4 ,(22*+(-+ { %.@+

4' 5 Q j K+ 8@'a= 0 +'= ; F@+

(22*+(-+ 4 )v Y D 4 . K Y >

6Y >

References : 1- World Health organization. Blood transfusion safety. Available at: http://www.who.int/bloodsafety/en/

Y(!\ / > +K O " YX! + 8 `= K+:" Y; 2b" !@ + Y;+ b6 > +K[!)V B.@+ 0" O

-

+ '6= E : >

!" G H' '! (! + 8/ " . | 7^ Q

6Y

:! .4'5

13- Cisneros-Castolo M, Hernandez L, Ibarra-Robles I, Fernandez-Garate I, Escobedo J. Prevalence of hepatitis B virus infection and related risk factors in a rural community of Mexico. Am Y Trop Med Hyg 2001; 65 (6) : 759-63. 14- Centers for Disease Control (CDC), MMWR Morb Mortal Wkly Rep. Changing patterns of groups at high risk for hepatitis B in the united States. 1988;37(28):429-32,437. 15- Sanchez M, Gonzalez B. Prevalence of type C and B hepatitis in blood donors at a third level hospital of Mexico city. Salud Publica Mex 1999;41(6):475-8. 16- Lewis-Ximenez L, Stuver Sh, Ginivino C, Silva J, Schatzmayr H, Yoshida C. Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil. BMC Public Health 2002;2:26.

4+ 9 - 8= 2O '$2 K )

.*

47!, 4 ,(22*+(-+

N)

0 +'= C B

! M-

Prevalence of hepatitis B and hepatitis C, and their risk factors among Guilan blood donors Mansour Ghanaei F.1,2(MD), Fallah M.S. 1(MS), Jafarshad R. 1(MD), Joukar F. 1,2(MS), Salari A. 1(MD),Tavafzadeh R. 1(MD) , Khoshsrour M. 1(MS) 1

Guilan Gasterointestinal and Liver Disease Research Center(GLDRC) Guilan University of Medical Sciences

2

Abstract Background and Objectives Millions of lives are saved each year through blood transfusion. Although blood is a lifesaving element, it can occassionally cause some severe diseases. This study was performed to assess the prevalence of hepatitis B and C virus infections and their known risk factors among Guilan blood donors from 1997 till 2002. Materials and Methods In this descriptive study, 221508 blood donors were referred to Guilan Blood Transfusion Center. ELISA test was performed for HBsAg and HCVAb detection. Positive cases of HBV and HCV were confirmed by neutralization and RIBA tests, respectively. Known risk factors including history of surgery, blood transfusion, and IV drug abuse were extracted from available medical documents for being evaluated. Results 997 patients were HBsAg positive and 3603 HCVAb positive. After performing confirmation tests, the prevalence rates of HBsAg and HCVAb were 0.45% and 0.32%, respectively; the rates of both were higher in males. The most common risk factors were in order history of surgery and the history of dental procedure in the past decade. Conclusions Due to several risk factors in blood donors, more studies are recommended in order to evaluate the correlation between prevalence of infections with one single risk factor as an independent variable without any factor intervening factors. Key words: Blood donation, Hepatitis B, Hepatitis C, Iran SJIBTO 2008; 4(5): 331-336

Received: 3 Dec 2006 Accepted: 23 Apr 2008

Correspondence: Mansour Ghanaei F., Profossor of Gastroentrology and Hepatology. Gastrointestinal and Liver Diseases Research Center. Guilan University of Medical Sciences. Sardar Jangal Ave. Rasht, Iran. Postal Code: 41448-95655.Tel: (+98131) 5535116; Fax : (+98131) 5534951 E-mail: [email protected]